{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:44:41Z","timestamp":1794977081995,"version":"4.9.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Mucormycosis is classified as the third leading cause of invasive fungal disease in immunocompromised patients and is characterized by high morbidity and mortality (33%\u201356%). The aim of this study is to describe presentation, treatment and outcome of Dutch pediatric hemato-oncology patients recently diagnosed with mucormycosis and to review the literature to gain more insight specifically into contemporary outcome data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Ten cases were diagnosed in the Princess M\u00e1xima Center for Pediatric Oncology from 2018 to 2021 and were retrospectively reviewed. In addition, 9 case series (n = 148) were included from literature.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In our case series, 5 patients of 10 children (age 2\u201317 years) had disseminated invasive fungal disease. Four patients had localized pulmonary disease and 1 had a localized renal infection. One diagnosis was made postmortem. The underlying diseases were acute lymphoblastic leukemia (n = 6), acute myeloid leukemia (n = 2) and lymphoma (n=2). Seven patients received combination therapy comprising of a lipid amphotericin B formulation and a triazole, surgery was performed in 67%. All neutropenic patients received granulocyte transfusions and\/or granulocyte colony-stimulating factor. Mucormycosis-related mortality was 20%. In the literature review, mucormycosis-related mortality was 36% for all patients and 66% for patients with disseminated disease. Survival rates were similar over the past 2 decades. The most common underlying disorder was acute lymphoblastic leukemia. Liposomal amphotericin B was the mainstay of treatment. Seventy percent of patients underwent surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Although survival of mucormycosis improved significantly overtime, it plateaued in the past decades. This series shows that with screening, early diagnostics and early antifungal and if possible surgical treatment, mortality is low and even disseminated disease is salvageable if approached aggressively with a combination of surgery and antifungal treatment. Further research focused on diagnostics, combination antifungal and adjunctive therapy is necessary to enhance the survival of mucormycosis in children.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003608","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T10:04:41Z","timestamp":1655287481000},"page":"e369-e376","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Mucormycosis in Children With Hematologic Malignancies: A Case Series and Review of the Literature"],"prefix":"10.1097","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6800-8058","authenticated-orcid":false,"given":"Yvette G. T.","family":"Loeffen","sequence":"first","affiliation":[{"name":"Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1644-0118","authenticated-orcid":false,"given":"Fenna","family":"Scharloo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University Medical Center Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-3228","authenticated-orcid":false,"given":"Bianca F.","family":"Goemans","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6601-7812","authenticated-orcid":false,"given":"Katja M. J.","family":"Heitink-Polle","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Princess M\u00e1xima Center for Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Lindemans","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, Pediatric Blood and Bone Marrow Transplantation, Prinses M\u00e1xima Center for Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-7677","authenticated-orcid":false,"given":"Tjomme","family":"van der Bruggen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-1916","authenticated-orcid":false,"given":"Ferry","family":"Hagen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom F. W.","family":"Wolfs","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/jpids\/piu074","article-title":"A prospective, international cohort study of invasive mold infections in children.","volume":"4","author":"Wattier","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPH.0000000000001468","article-title":"Frequency and determinants of invasive fungal infections in children with solid and hematologic malignancies in a nonallogeneic stem cell transplantation setting: a narrative review.","volume":"41","author":"Ruijters","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"issue":"suppl_1","key":"R3-20250614","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/jpids\/pix053","article-title":"Recognition and clinical presentation of invasive fungal disease in neonates and children.","volume":"6","author":"King","year":"2017","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"suppl 1","key":"R4-20250614","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis.","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/myc.12010","article-title":"Focus on invasive mucormycosis in paediatric haematology oncology patients: a series of 11 cases.","volume":"56","author":"Phulpin-Weibel","year":"2013","journal-title":"Mycoses"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1043454218763092","article-title":"Mucormycosis: early identification of a deadly fungus [formula: see text].","volume":"35","author":"Brettholz","year":"2018","journal-title":"J Pediatr Oncol Nurs"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/myc.12862","article-title":"Invasive mucormycosis in children with cancer: a retrospective study from the Infection Working Group of Italian Pediatric Hematology Oncology Association.","volume":"62","author":"Muggeo","year":"2019","journal-title":"Mycoses"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.16329","article-title":"Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia.","volume":"189","author":"Elitzur","year":"2020","journal-title":"Br J Haematol"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/myc.12915","article-title":"Overview and outcome of mucormycosis among children with cancer: report from the Children\u2019s Cancer Hospital Egypt.","volume":"62","author":"Madney","year":"2019","journal-title":"Mycoses"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"suppl_1","key":"R11-20250614","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis.","volume":"56","author":"Skiada","year":"2018","journal-title":"Med Mycol"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s12879-016-2005-1","article-title":"Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries.","volume":"16","author":"Pana","year":"2016","journal-title":"BMC Infect Dis"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jpids\/piz007","article-title":"Pediatric mucormycosis: a 10-year systematic review of reported cases and review of the literature.","volume":"8","author":"Otto","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MPH.0000000000001931","article-title":"Invasive mucormycosis in children with malignancies: report from the Infection Working Group of the Hellenic Society of Pediatric Hematology-Oncology.","volume":"43","author":"Antoniadi","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group education and research consortium.","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"e0029021","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients.","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/MPH.0b013e3181bbc516","article-title":"Zygomycetes infections in pediatric hematology oncology patients: a case series and review of the literature.","volume":"31","author":"Dehority","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1111\/j.1439-0507.2011.02025.x","article-title":"Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases.","volume":"54","author":"D\u00e4britz","year":"2011","journal-title":"Mycoses"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"e27834","DOI":"10.1002\/pbc.27834","article-title":"Mucormycosis diagnosed during induction chemotherapy in five pediatric patients with acute lymphoblastic leukemia.","volume":"66","author":"Aftandilian","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"11","DOI":"10.24953\/turkjped.2021.01.002","article-title":"Mucormycosis in a pediatric population: a review of 20 cases from southern Turkey.","volume":"63","author":"Alabaz","year":"2021","journal-title":"Turk J Pediatr"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis.","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0179136","article-title":"Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates.","volume":"12","author":"Guinea","year":"2017","journal-title":"PLoS One"},{"key":"R23-20250614","first-page":"1149","article-title":"Deaths attributable to carbapenem-resistant enterobacteriaceae infections.","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg Infect Dis J"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/1040841X.2012.711741","article-title":"Mucormycosis treated with posaconazole: review of 96 case reports.","volume":"39","author":"Vehreschild","year":"2013","journal-title":"Crit Rev Microbiol"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1439-0507.2011.02124.x","article-title":"Trends in zygomycosis in children.","volume":"55","author":"Prasad","year":"2012","journal-title":"Mycoses"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"562610","DOI":"10.1155\/2014\/562610","article-title":"Clinical features and outcome of mucormycosis.","volume":"2014","author":"Camara-Lemarroy","year":"2014","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J Infect Dis"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.3390\/jof6040268","article-title":"Introduction of a comprehensive diagnostic and interdisciplinary management approach in haematological patients with mucormycosis: a pre and post-intervention analysis.","volume":"6","author":"Risum","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.3390\/jof5010024","article-title":"Molecular strategies to diagnose mucormycosis.","volume":"5","author":"Millon","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/mmy\/myaa036","article-title":"Interlaboratory evaluation of Mucorales PCR assays for testing serum specimens: a study by the fungal PCR Initiative and the Modimucor study group.","volume":"59","author":"Rocchi","year":"2021","journal-title":"Med Mycol"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"e00653","DOI":"10.1128\/AAC.00653-19","article-title":"A revised species concept for opportunistic mucor species reveals species-specific antifungal susceptibility profiles.","volume":"63","author":"Wagner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"ofaa646","DOI":"10.1093\/ofid\/ofaa646","article-title":"Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents.","volume":"8","author":"Miller","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"101007","DOI":"10.1016\/j.mycmed.2020.101007","article-title":"Mucormycosis treatment: recommendations, latest advances, and perspectives.","volume":"30","author":"Brunet","year":"2020","journal-title":"J Mycol Med"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"e01783","DOI":"10.1128\/AAC.01783-19","article-title":"A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation.","volume":"64","author":"Decembrino","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.","volume":"58","author":"Schwartz","year":"2020","journal-title":"Med Mycol"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3389\/fmicb.2018.01612","article-title":"Immunomodulation as therapy for fungal infection: are we closer?","volume":"9","author":"Sam","year":"2018","journal-title":"Front Microbiol"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1182\/blood-2015-05-645986","article-title":"Efficacy of transfusion with granulocytes from G-CSF\/dexamethasone-treated donors in neutropenic patients with infection.","volume":"126","author":"Price","year":"2015","journal-title":"Blood"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.transci.2018.02.009","article-title":"Granulocyte transfusions in the management of neutropenic fever: a pediatric perspective.","volume":"57","author":"Gurlek Gokcebay","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"R41-20250614","first-page":"CD005341","article-title":"Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction.","volume":"2015","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1469-0691.2005.01170.x","article-title":"Hyperbaric oxygen as an adjunctive treatment for zygomycosis.","volume":"11","author":"John","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"R43-20250614","doi-asserted-by":"crossref","first-page":"e02589-16","DOI":"10.1128\/AAC.02589-16","article-title":"Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis.","volume":"61","author":"Gebremariam","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:10:18Z","timestamp":1749946218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003608","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}